Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 186 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo to Methotrexate Clear all
Completed Phase 1 Interventional

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

NCT00686868
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
placebo, ofatumumab
Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Anniston, Alabama • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

NCT02885181
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
DeBary, Florida • Sarasota, Florida • Canton, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

NCT00299182
View directory record Official record
Conditions
Lymphoma
Interventions
AMG 531, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CE-224,535, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Mesa, Arizona • DeBary, Florida • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

NCT01009242
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis
Interventions
CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate
Biological · Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

NCT02706951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

NCT01855789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
155
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 14, 2026, 2:24 PM EDT
Terminated Phase 1 Interventional Results available

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Edecesertib, Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 14, 2026, 2:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

NCT00195494
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Methotrexate, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study of IA-14069

NCT05533372
View directory record Official record
Conditions
Healthy, Rheumatoid Arthritis
Interventions
IA-14069, Placebo, Methotrexate
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

NCT00659412
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Alefacept, Methotrexate, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Birmingham, Alabama • Wheaton, Maryland • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 14, 2026, 2:24 PM EDT
Terminated Phase 2Phase 3 Interventional

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

NCT00042406
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Humax-CD4, Placebo
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
50
States / cities
Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

NCT06073093
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Northridge, California • Upland, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 14, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of AMG 827 in Subjects With RA

NCT01059448
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AMG 827
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Inflammation and Coronary Endothelial Function

NCT02366091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methotrexate, Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 14, 2026, 2:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

NCT01373151
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab
Drug · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis

NCT01749787
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PRTX-100 at 1.5 mcg/kg, PRTX-100 at 3.0 mcg/kg, PRTX-100 at 6.0 mcg/kg, PRTX-100 at 12.0 mcg/kg, PRTX-100 at 240 mcg, Placebo, PRTX-100 at 420 mcg
Drug
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Coeur d'Alene, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450, Placebo oral tablet, Methotrexate
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Anniston, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 14, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00264550
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
13
States / cities
Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 14, 2026, 2:24 PM EDT